Variation in use of androgen suppression with external-beam radiotherapy for nonmetastatic prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 83, Issue 1, 2012, Pages 8-15

  Swisher Mcclure, Samuel ^a   Pollack, Craig E ^d   Christodouleas, John P ^a,c   Guzzo, Thomas J ^b   Haas, Naomi B ^b,c   Vapiwala, Neha ^a,c   Bekelman, Justin E ^a,b,c  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen suppression; External beam radiation; Health services research; Prostate cancer; Quality of care

Indexed keywords

ANDROGEN SUPPRESSION; COMORBIDITY; DEMOGRAPHIC CHARACTERISTICS; DETROIT; DISEASE RISKS; HEALTH SERVICES RESEARCH; HIGH-RISK PATIENTS; KENTUCKY; LOCALIZED PROSTATE CANCER; MULTIVARIATE LOGISTIC REGRESSIONS; PATIENT EDUCATION; PROSTATE CANCERS; QUALITY OF CARE;

HEALTH INSURANCE; LOGISTICS; RADIOTHERAPY;

DISEASES;

GONADORELIN AGONIST;

AGED; ANDROGEN DEPRIVATION THERAPY; CANCER HORMONE THERAPY; CANCER RISK; CASTRATION; COMORBIDITY; CONFERENCE PAPER; EXTERNAL BEAM RADIOTHERAPY; HEALTH CARE UTILIZATION; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; GUIDELINE ADHERENCE; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEER PROGRAM; TREATMENT OUTCOME; UNITED STATES; UNNECESSARY PROCEDURES;

EID: 84859844553     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.06.1951     Document Type: Conference Paper

References (20)

1. C. Huggins, and C.V. Hodges Studies on prostate cancer. 1. The effects of castration, or estrogen and androgen injection on serum phosphates in metastatic carcinoma of the prostate Cancer Res 1 1941 293 297
2. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial Lancet 360 2002 103 106
3. M.V. Pilepich, K. Winter, and M.J. John Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252
4. A.V. D'Amico, J. Manola, and M. Loffredo 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial JAMA 292 2004 821 827
5. M.V. Pilepich, K. Winter, and C.A. Lawton Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: Long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290
6. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456
7. H. Lee, K. McGovern, and J.S. Finkelstein Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma Cancer 104 2005 1633 1637
8. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer:1996-2010. Available through http://www.nccn.org. Accessed 11/1/2010.
9. V.B. Shahinian, Y.F. Kuo, and J.L. Freeman Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma Cancer 103 2005 1615 1624
10. V.B. Shahinian, Y.F. Kuo, and S.M. Gilbert Reimbursement policy and androgen-deprivation therapy for prostate cancer N Engl J Med 363 2010 1822 1832
11. C.J. Weight, E.A. Klein, and J.S. Jones Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population Cancer 112 2008 2195 2201
12. J.L. Warren, C.N. Klabunde, and D. Schrag Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population Med Care 40 2002 IV-3 IV18
13. Y.N. Wong, N. Mitra, and G. Hudes Survival associated with treatment vs observation of localized prostate cancer in elderly men JAMA 296 2006 2683 2693
14. Method to calculate hormone therapy for men with prostate cancer. In: Analytic Support for Researchers. SEER-Medicare Linked Database. http://healthservices.cancer.gov/seermedicare/considerations/prostate.html. Last accessed October 3, 2011.
15. A. Elixhauser, C. Steiner, and D. Harris Comorbidity measures for use with administrative data Med Care 36 1998 8 27
16. M.R. Painter Reimbursement issues with hormonal therapies for prostate cancer Rev Urol 7 Suppl 5 2005 S44 S47
17. P.L. Nguyen, M.H. Chen, and C.J. Beard Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: A postrandomization analysis by risk group Int J Radiat Oncol Biol Phys 77 2010 1046 1052
18. C. Vogeli, A.E. Shields, and T.A. Lee Multiple chronic conditions: Prevalence, health consequences, and implications for quality, care management, and costs J Gen Intern Med 22 Suppl 3 2007 391 395
19. A.V. D'Amico, M.H. Chen, and A.A. Renshaw Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial JAMA 299 2008 289 295
20. J.A. Efstathiou, K. Bae, and W.U. Shipley Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31 J Clin Oncol 27 2009 92 99